Sectors

RCUS
Arcus Biosciences, Inc.
29.28
300 x 23.50
200 x 29.12
bid
ask
+
0.07
0.24%
250 @ 07:56 PM
29.28 +0.00 (0.00%)
Ytd22.87%
1y176.49%
28.23
day range
29.34
10.55
52 week range
31.73
Open28.89Prev Close29.21Low28.23High29.34Mkt Cap3.68B
Vol1.11MAvg Vol1.29MEPS-3.94P/EN/AForward P/E-8.76
Beta0.81Short Ratio12.61Inst. Own74.67%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning10-2750-d Avg29.09200-d Avg24.421yr Est38.33

RCUS News

Arcus Biosciences to Participate in Three Upcoming Investor Conferences
businesswire.com
Arcus Biosciences to Participate in Three Upcoming Investor Conferences

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmac

BlackRock Inc. Makes New $506.11 Million Investment in Arcus Biosciences, Inc. $RCUS
defenseworld.net
BlackRock Inc. Makes New $506.11 Million Investment in Arcus Biosciences, Inc. $RCUS

BlackRock Inc. bought a new stake in Arcus Biosciences, Inc. (NYSE: RCUS) during the second quarter,

Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
prnewswire.com
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm

NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inves

Arcus Biosciences Announces New Employment Inducement Grants
businesswire.com
Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biop

Arcus Biosciences Q2 Earnings Call Highlights
marketbeat.com
Arcus Biosciences Q2 Earnings Call Highlights

Arcus Biosciences NYSE: RCUS outlined plans to expand development of its casdatifan cancer program a

benzinga.com
Wells Fargo Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $26

Wells Fargo analyst Eva Fortea Verdejo maintains Arcus Biosciences (NYSE:RCUS) with a Equal-Weigh

benzinga.com
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $43

Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and rai

Arcus Biosciences, Inc. (RCUS) Q2 2026 Earnings Call Transcript
seekingalpha.com
Arcus Biosciences, Inc. (RCUS) Q2 2026 Earnings Call Transcript

Arcus Biosciences, Inc. (RCUS) Q2 2026 Earnings Call Transcript

Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates
zacks.com
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates

Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $0.72 per share versus the Zacks Co

benzinga.com
Arcus Biosciences Q2 EPS $(0.72) Beats $(0.87) Estimate, Sales $41.000M Beat $23.405M Estimate

Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(0.72) per share which beat the analyst

Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
businesswire.com
Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biop

Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
globenewswire.com
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is i

Arcus Biosciences Announces New Employment Inducement Grants
businesswire.com
Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biop

SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study
zacks.com
SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study

Summit announces updated HARMONi overall survival data and partners with Arcus to test ivonescimab i

benzinga.com
Arcus Biosciences Announces A Clinical Supply Agreement With AVEO Oncology To Evaluate Casdatifan;

This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational c

Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients
businesswire.com
Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in C

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global bio

benzinga.com
Arcus Biosciences And Summit Therapeutics Announced A Clinical Trial Collaboration To Evaluate The S

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on d

Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
businesswire.com
Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdat

HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, gl

Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
businesswire.com
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdat

HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)---- $SMMT--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical

Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates
businesswire.com
Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipel

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmac

Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?
benzinga.com
Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?

HC Wainwright raised its price forecast for Arcus Biosciences Inc. (NASDAQ:RCUS), citing the aggress

Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?
benzinga.com
Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?

HC Wainwright lifted Arcus Biosciences' price target, citing broader revenue potential for casda

benzinga.com
HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $45

HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences (NYSE:RCUS) with a Buy a

An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run
fool.com
An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run

This sale was executed under a Rule 10b5-1 plan following a 203% one-year surge.

Arcus Biosciences Announces New Employment Inducement Grants
businesswire.com
Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biop

benzinga.com
Arcus Biosciences Announces Publication In Nature Describing New Research From The ARC-20 Study Show

This is the first study to comprehensively interconnect clinical outcomes from patients receiving a

New Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan
businesswire.com
New Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Canc

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global bio

Arcus Biosciences Announces New Employment Inducement Grants
businesswire.com
Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biop

benzinga.com
Arcus Biosciences Enters Clinical Trial Collaboration And Supply Agreement With Bristol Myers Squibb

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on d

benzinga.com
Truist Securities Assumes Arcus Biosciences at Buy, Raises Price Target to $35

Truist Securities analyst Supawat Thongthip assumes Arcus Biosciences (NYSE:RCUS) with a Buy rati

benzinga.com
Morgan Stanley Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $22

Morgan Stanley analyst Terence Flynn maintains Arcus Biosciences (NYSE:RCUS) with a Equal-Weight

benzinga.com
Goldman Sachs Maintains Buy on Arcus Biosciences, Raises Price Target to $34

Goldman Sachs analyst Richard Law maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises

benzinga.com
Arcus Biosciences Q1 EPS $(1.02) Misses $(0.93) Estimate, Sales $17.000M Miss $29.484M Estimate

Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(1.02) per share which missed the analys

Earnings Scheduled For May 5, 2026
benzinga.com
Earnings Scheduled For May 5, 2026

What's Going On With Arcus Biosciences Stock On Wednesday?
benzinga.com
What's Going On With Arcus Biosciences Stock On Wednesday?

Arcus Biosciences halts STAR-121 lung cancer trial after futility review while Gilead Science declin

benzinga.com
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $41

Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and rai

benzinga.com
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $45

Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises

benzinga.com
Leerink Partners Maintains Outperform on Arcus Biosciences, Raises Price Target to $49

Leerink Partners analyst Geoffrey Porges maintains Arcus Biosciences (NYSE:RCUS) with a Outperfor

The Analyst Verdict: Arcus Biosciences In The Eyes Of 5 Experts
benzinga.com
The Analyst Verdict: Arcus Biosciences In The Eyes Of 5 Experts

benzinga.com
HC Wainwright & Co. Reiterates Buy on Arcus Biosciences, Maintains $32 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates Arcus Biosciences (NYSE:RCUS) with a Buy

Arcus Biosciences Earnings Review: Q4 Summary
benzinga.com
Arcus Biosciences Earnings Review: Q4 Summary

benzinga.com
Arcus Biosciences Q4 EPS $(0.89) Beats $(1.03) Estimate, Sales $33.000M Miss $35.711M Estimate

Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(0.89) per share which beat the analyst

Earnings Scheduled For February 25, 2026
benzinga.com
Earnings Scheduled For February 25, 2026

This Inspire Medical Systems Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
benzinga.com
This Inspire Medical Systems Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday

What Analysts Are Saying About Arcus Biosciences Stock
benzinga.com
What Analysts Are Saying About Arcus Biosciences Stock

benzinga.com
Wells Fargo Downgrades Arcus Biosciences to Equal-Weight, Lowers Price Target to $23

Wells Fargo analyst Eva Fortea Verdejo downgrades Arcus Biosciences (NYSE:RCUS) from Overweight t

benzinga.com
Goldman Sachs Upgrades Arcus Biosciences to Buy, Raises Price Target to $28

Goldman Sachs analyst Richard Law upgrades Arcus Biosciences (NYSE:RCUS) from Neutral to Buy and

benzinga.com
Morgan Stanley Downgrades Arcus Biosciences to Equal-Weight, Lowers Price Target to $20

Morgan Stanley analyst Terence Flynn downgrades Arcus Biosciences (NYSE:RCUS) from Overweight to

Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug
benzinga.com
Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug

Arcus ends its Phase 3 STAR-221 trial after a futility review and shifts R&D toward casdatifan,

benzinga.com
HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $32

HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences (NYSE:RCUS) with a Buy a